Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells

MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks

(2011) Michael Fraser et al.   CELL CYCLE

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Targeting the Akt/mTOR pathway in Brca1-deficient cancers

(2011) T Xiang et al.   ONCOGENE

What Is the Difference Between Triple-Negative and Basal Breast Cancers?

(2010) Melanie D. Seal et al.   CANCER JOURNAL

Distinct Biological Roles for the Akt Family in Mammary Tumor Progression: Figure 1.

(2010) Rachelle L. Dillon et al.   CANCER RESEARCH

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

(2010) Ana Bosch et al.   CANCER TREATMENT REVIEWS

BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells

(2010) Gemma Molyneux et al.   Cell Stem Cell

AKT regulates BRCA1 stability in response to hormone signaling

(2010) Andrew C. Nelson et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Targeted cancer therapies

(2010) Saurabh Aggarwal   NATURE REVIEWS DRUG DISCOVERY

Loss of BRCA1 leads to an increased sensitivity to Bisphenol A

(2010) Laundette P. Jones et al.   TOXICOLOGY LETTERS

Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development

(2009) J. Fasano et al.   ANNALS OF ONCOLOGY

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

(2009) Elena López-Knowles et al.   INTERNATIONAL JOURNAL OF CANCER

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Negative Regulation of AKT Activation by BRCA1

(2008) T. Xiang et al.   CANCER RESEARCH

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

PKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival

(2008) Lana Bozulic et al.   MOLECULAR CELL